EDP-978 Phase 1 Study in Healthy Adults, Chronic Urticaria
Summary
A Phase 1 clinical trial for EDP-978, an oral drug candidate for Chronic Inducible Urticaria and Chronic Spontaneous Urticaria, has been registered on ClinicalTrials.gov. The randomized, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses in healthy adult subjects.
“This study is a randomized, double-blind, sponsor-open, placebo-controlled study.”
What changed
EDP-978, an oral drug candidate, has entered Phase 1 clinical development for chronic urticaria indications. The trial will evaluate single and multiple doses in healthy adults. This is a study registration entry in the ClinicalTrials.gov registry — it does not create compliance obligations or regulatory approvals.
Pharmaceutical companies and clinical investigators interested in urticaria therapeutics may use this registry entry to identify ongoing competitive trials or potential collaboration opportunities. Sponsors of competing urticaria programs should monitor Phase 1 results for EDP-978 as the development progresses.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
Phase 1 NCT07540910 Kind: PHASE1 Apr 21, 2026
Abstract
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.
Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: EDP-978, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.